Quotient, CytoAgents develop COVID-19 cytokine storm treatment

By The Science Advisory Board staff writers

April 28, 2020 -- A new collaboration between Quotient Sciences and CytoAgents will accelerate the development of a lead COVID-19 drug candidate to human clinical trials, the companies announced.

The partnership will focus on rapid development of CytoAgents' lead COVID-19 drug candidate, GP1681, for phase I and II trials in 2020. The candidate is a small-molecule inhibitor of cytokine release in activated human immune cells that shows potential in blocking the "cytokine storms" associated with severe illness in COVID-19 cases.

Under the agreement, CytoAgents will use Quotient's formulation and manufacturing expertise to develop and rapidly supply drug product for clinical trials. Quotient will also work to develop a scalable solid oral dosage form for larger patient trials. The program will be conducted at Quotient's specialized drug handling and containment facility in Pennsylvania.

Theravance's Janus kinase inhibitor enters phase I for ARDS
Biopharmaceutical company Theravance Biopharma has begun a phase I study in the U.K. for a drug to help prevent the development of acute respiratory distress...

Copyright © 2020 scienceboard.net


Conferences
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter